The Life Sciences Strategy Summit on IP and Exclusivity is a premier annual event convening pharmaceutical, biotech, and legal professionals to explore the evolving landscape of intellectual property and regulatory exclusivity. Scheduled for October 2025 in Munich, Germany, the summit offers a platform for in-depth discussions on patent strategies, regulatory frameworks, and market exclusivity challenges.​
Attendees can anticipate sessions on the latest developments in Supplementary Protection Certificates (SPCs), including the implications of recent CJEU decisions and the SPC waiver's impact on both generic and innovator strategies. The conference will also delve into the intersection of regulatory and IP law, with topics covering clinical trials, data exclusivity, and the Pharmaceutical Strategy for Europe. Additionally, panels will address patentability requirements within the life sciences industry, focusing on patent quality, the G2/21 decision, enablement, and the role of the Patent Trial and Appeal Board (PTAB). The influence of the Unified Patent Court (UPC) on life science strategies will also be a key discussion point, featuring industry-led sessions and a judges panel .​
Preceding the main summit, the SPC and PTE Forum offers a focused day on October 8, 2025, dedicated to SPC strategies, including updates on litigation, the Unitary SPC proposal, and foundational knowledge essential for patent practitioners .​
With over 65 speakers and participants from more than 26 countries, the summit provides unparalleled networking opportunities and insights into shaping robust IP and regulatory strategies for the future .​
Attendees can anticipate sessions on the latest developments in Supplementary Protection Certificates (SPCs), including the implications of recent CJEU decisions and the SPC waiver's impact on both generic and innovator strategies. The conference will also delve into the intersection of regulatory and IP law, with topics covering clinical trials, data exclusivity, and the Pharmaceutical Strategy for Europe. Additionally, panels will address patentability requirements within the life sciences industry, focusing on patent quality, the G2/21 decision, enablement, and the role of the Patent Trial and Appeal Board (PTAB). The influence of the Unified Patent Court (UPC) on life science strategies will also be a key discussion point, featuring industry-led sessions and a judges panel .​
Preceding the main summit, the SPC and PTE Forum offers a focused day on October 8, 2025, dedicated to SPC strategies, including updates on litigation, the Unitary SPC proposal, and foundational knowledge essential for patent practitioners .​
With over 65 speakers and participants from more than 26 countries, the summit provides unparalleled networking opportunities and insights into shaping robust IP and regulatory strategies for the future .​
